On Thursday, cystic fibrosis powerhouse Vertex Pharmaceuticals Inc. reported solid first-quarter sales of its drugs, Kalydeco (ivacaftor) and Orkambi (lumacaftor/ivacaftor), designed to modulate CFTR, which is mutated in cystic fibrosis patients, but it was the pipeline of next-generation drugs that received the most attention. Read More
